{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:06Z","timestamp":1794047406636,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2021.280259","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T02:59:14Z","timestamp":1640228354000},"page":"1226-1228","source":"Crossref","is-referenced-by-count":3,"title":["Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review"],"prefix":"10.3324","volume":"107","author":[{"given":"Lijie","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linna","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"35986","doi-asserted-by":"crossref","unstructured":"Eyre TA, Fox CP, Boden A. Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme. Br J Haematol. 2019; 184(4):667-671.","DOI":"10.1111\/bjh.15151"},{"key":"35987","doi-asserted-by":"crossref","unstructured":"Gordon MJ, Raess PW, Young K. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. Br J Haematol. 2017; 179(3):501-503.","DOI":"10.1111\/bjh.14224"},{"key":"35988","unstructured":"Algrin C, Chapiro E, Saviellis J. B-Cell prolymphocytic leukemia, a rare lymphoproliferative disorder: analysis of 35 cases, a study on behalf of the French Innovative Leukemia Organization (FILO). Blood. 2017; 130(Suppl 1):S4310."},{"key":"35989","doi-asserted-by":"crossref","unstructured":"Coelho H, Badior M, Melo T. Sequential kinase inhibition (idelalisib\/ ibrutinib) induces clinical remission in B-cell prolymphocytic leukemia harboring a 17p deletion. Case Rep Hematol. 2017; 2017:8563218.","DOI":"10.1155\/2017\/8563218"},{"key":"35990","doi-asserted-by":"crossref","unstructured":"Damlaj M, Al Balwi M, Al Mugairi AM. Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. Leuk Lymphoma. 2018; 59(3):739-742.","DOI":"10.1080\/10428194.2017.1347653"},{"key":"35991","doi-asserted-by":"crossref","unstructured":"Bindra BS, Kaur H, Portillo S. B-cell prolymphocytic leukemia: case report and challenges on a diagnostic and therapeutic forefront. Cureus. 2019; 11(9):e5629.","DOI":"10.7759\/cureus.5629"},{"key":"35992","doi-asserted-by":"crossref","unstructured":"Patil N, Went RG. Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors. Br J Haematol. 2019; 186(4):e80-e82.","DOI":"10.1111\/bjh.15912"},{"key":"35993","doi-asserted-by":"crossref","unstructured":"Christoforidou A, Bezirgiannidou Z, Vrachiolias G. B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax. Leuk Lymphoma. 2020; 61(3):749-752.","DOI":"10.1080\/10428194.2019.1689392"},{"key":"35994","doi-asserted-by":"crossref","unstructured":"George P, Brown A, Weinkove R. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3\/IGH translocation: response to ibrutinib. Pathology. 2020; 52(4):491-492.","DOI":"10.1016\/j.pathol.2020.03.005"},{"key":"35995","doi-asserted-by":"crossref","unstructured":"Oka S, Ono K, Nohgawa M. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia. Invest New Drugs. 2020; 38(5):1598-1600.","DOI":"10.1007\/s10637-020-00902-9"},{"key":"35996","doi-asserted-by":"crossref","unstructured":"Moore J, Baran AM, Meacham PJ. Initial treatment of B-cell prolymphocytic leukemia with ibrutinib. Am J Hematol. 2020; 95(5):E108-E110.","DOI":"10.1002\/ajh.25733"},{"key":"35997","doi-asserted-by":"crossref","unstructured":"Shindiapina P, Brown JR, Danilov AV. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Br J Haematol. 2014; 167(2):149-161.","DOI":"10.1111\/bjh.13042"},{"key":"35998","doi-asserted-by":"crossref","unstructured":"Chamuleau MED, Burggraaff CN, Nijland M. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica. 2020; 105(12):2805-2812.","DOI":"10.3324\/haematol.2019.238162"},{"key":"35999","doi-asserted-by":"crossref","unstructured":"Buhler A, Wendtner CM, Kipps TJ. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016; 6(3):e404.","DOI":"10.1038\/bcj.2016.9"},{"key":"36000","doi-asserted-by":"crossref","unstructured":"Fink AM, Bahlo J, Robrecht S. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, doubleblind, phase 3 study. Lancet Haematol. 2017; 4(10):e475-e486.","DOI":"10.1016\/S2352-3026(17)30171-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280259\/73938","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280259\/74451","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10481\/73938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:47Z","timestamp":1794045647000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.280259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.280259","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}